Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2023-12-19 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
股票解除限售公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the lifting of stock trading restrictions (解除限售公告) for certain shareholders of Beijing Xinghao Pharmaceutical Co., Ltd. It details the number of shares becoming tradable, the shareholders involved, reasons for lifting restrictions, and the updated share capital structure. There is no financial performance data, no discussion of earnings, no management commentary, and no regulatory certification. The document is a formal disclosure about share trading status changes, specifically about shares becoming unrestricted and tradable. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share status changes that does not fit into more specific categories like Share Issue/Capital Change or Director's Dealing. The document length is 2564 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the best classification is Regulatory Filings (RNS).
2023-12-19 Chinese
国浩律师（上海）事务所关于北京星昊医药股份有限公司2023年第六次临时股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of the 2023 sixth extraordinary general meeting (临时股东大会) of Beijing Xinghao Pharmaceutical Co., Ltd. It details the legality and validity of the meeting process, attendees' qualifications, proposals considered, and voting results. The document does not contain financial statements, earnings data, or management discussion of financial results. It is a formal legal opinion related to a shareholders' meeting, focusing on procedural compliance and voting outcomes. This type of document is best classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official voting results and meeting procedural confirmations from a shareholders' meeting.
2023-12-13 Chinese
第六届董事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, attendance, and specific board decisions such as the election of a new independent director and committee member. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes and appointments within the board and committees, which aligns with announcements related to board or management information. The document length is short (1291 characters), and it is not a report or a report announcement but a meeting resolution announcement. Therefore, the most appropriate classification is Board/Management Information (MANG).
2023-12-13 Chinese
2023年第六次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 sixth extraordinary general meeting of shareholders of Beijing Xinghao Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, agenda items, voting results, and changes in board members. The content focuses on the official voting results and decisions made during the shareholders' meeting. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a proxy solicitation or investor presentation. The document is not a brief announcement of a report publication but a full disclosure of voting outcomes and resolutions. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (4683 characters) and detailed voting data support this classification with high confidence.
2023-12-13 Chinese
2023年股权激励计划限制性股票授予结果公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the results of a restricted stock grant under a 2023 equity incentive plan by Beijing Xinghao Pharmaceutical Co., Ltd. It includes specifics such as grant date, number of shares granted, recipients, performance conditions, and impact on shareholding structure. It also references a verification report by an accounting firm. The content focuses on the equity incentive plan's stock grant results and related disclosures rather than financial statements or earnings. This type of document is a formal announcement of share-based compensation awards to employees and management, which fits the category of a Capital/Financing Update (CAP) because it relates to changes in the company's capital structure through stock grants and repurchases for the incentive plan. It is not an annual or interim report, audit report, earnings release, or management discussion. It is not a regulatory filing or report publication announcement since it contains substantive details about the stock grant. Therefore, the best classification is Capital/Financing Update (CAP).
2023-12-06 Chinese
第七届监事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a meeting resolution announcement from the supervisory board of Beijing Xinghao Pharmaceutical Co., Ltd. It details the convening and attendance of the meeting, the agenda item about changing the company's auditor, and the voting results. It does not contain any financial statements or detailed audit reports but rather announces a decision related to audit firm change. The document length is short (923 characters) and it is an announcement of a board/management decision rather than a full report or audit document. Therefore, it fits best under Board/Management Information (MANG).
2023-12-03 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.